Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cardiovascular Research

• Publication date

  2003-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0008-6363(03)00464-4PMID 14522423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ceramide-induced and Age-associated Increase in Macrophage COX-2 Expression Is Mediated through Up-regulation of NF-κB Activity*

  2003cited by this paper
• Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice.

  2002cited by this paper
• Simvastatin Promotes Atherosclerotic Plaque Stability in ApoE-Deficient Mice Independently of Lipid Lowering

  2002cited by this paper
• COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression

  2002cited by this paper
• Cyclooxygenase-2 inhibition and cardiovascular events.

  2002cited by this paper
• Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor*

  2002cited by this paper
• Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty.

  2002cited by this paper
• Regulation of cyclooxygenase‐2 by nitric oxide in activated hepatic macrophages during acute endotoxemia

  2002cited by this paper
• Characteristics of Intact and Ruptured Atherosclerotic Plaques in Brachiocephalic Arteries of Apolipoprotein E Knockout Mice

  2002cited by this paper
• Induction of Tissue Factor Expression in Human Endothelial Cells by CD40 Ligand Is Mediated via Activator Protein 1, Nuclear Factor κB, and Egr-1*

  2002cited by this paper
• Protease-Activated Receptors Upregulate Cyclooxygenase-2 Expression in Human Endothelial Cells

  2002cited by this paper
• Induction of cyclooxygenase-2 by heat shock protein 60 in macrophages and endothelial cells.

  2002cited by this paper
• Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice

  2002cited by this paper
• Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1.

  2002cited by this paper
• Morphological Predictors of Arterial Remodeling in Coronary Atherosclerosis

  2002cited by this paper
• Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-κB/IκB- and ERK2-dependent mechanisms

  2002cited by this paper
• Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms.

  2002cited by this paper
• Monocyte Membrane Type 1-Matrix Metalloproteinase

  2001cited by this paper
• Going from immutable to mutable atherosclerotic plaques.

  2001cited by this paper
• Risk of cardiovascular events associated with selective COX-2 inhibitors.

  2001cited by this paper
• Inducible Nitric Oxide Synthase Deficiency Does Not Affect the Susceptibility of Mice to Atherosclerosis but Increases Collagen Content in Lesions

  2001cited by this paper
• Unstable coronary plaque and its relation to coronary calcium.

  2001cited by this paper
• Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability

  2001cited by this paper
• Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response

  2001cited by this paper
• Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 expression.

  2001cited by this paper
• Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice.

  2000cited by this paper
• Visualization of Fibrous Cap Thickness and Rupture in Human Atherosclerotic Carotid Plaque In Vivo With High-Resolution Magnetic Resonance Imaging

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Advanced Atherosclerotic Lesions in the Innominate Artery of the ApoE Knockout Mouse

  2000cited by this paper
• Deficiency in Inducible Nitric Oxide Synthase Results in Reduced Atherosclerosis in Apolipoprotein E-Deficient Mice

  2000cited by this paper
• Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.

  1999cited by this paper
• Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis.

  1999cited by this paper
• Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomerulonephritis.

  1999cited by this paper
• Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice.

  1999cited by this paper
• Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase.

  1999cited by this paper
• Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages.

  1999cited by this paper
• Role and regulation of cyclooxygenase-2 during inflammation.

  1999cited by this paper
• Cyclooxygenase in biology and disease

  1998cited by this paper
• Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis

  1998cited by this paper
• Tissue factor modulates the thrombogenicity of human atherosclerotic plaques.

  1997cited by this paper
• Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2.

  1996cited by this paper
• Prostaglandin E1 reduces the glomerular mRNA expression of monocyte-chemoattractant protein 1 in anti-thymocyte antibody-induced glomerular injury.

  1996cited by this paper
• Molecular bases of the acute coronary syndromes.

  1995cited by this paper
• Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.

  1994cited by this paper
• Differential regulation of interleukin-6, macrophage inflammatory protein-1, and JE/MCP-1 cytokine expression in macrophage cell lines.

  1991cited by this paper
• Differential regulation of lnterleukin-6, macrophage inflammatory protein-1, and JE/MCP-1 cytokine expression in macrophage cell lines☆

  1991cited by this paper
• Immune mechanisms in atherosclerosis.

  1989cited by this paper
• Demonstration of all connective tissue elements in a single section; pentachrome stains.

  1955cited by this paper

• Recommendations for Design, Execution, and Reporting of Studies on Experimental Thoracic Aortopathy in Preclinical Models

  2025cites this paper
• Prostanoids in Cardiac and Vascular Remodeling

  2024cites this paper
• The diverse roles of macrophages in metabolic inflammation and its resolution

  2023cites this paper
• New horizons in the roles and associations of COX-2 and novel natural inhibitors in cardiovascular diseases

  2021cites this paper
• Celecoxib alleviates pathological cardiac hypertrophy and fibrosis via M1-like macrophage infiltration in neonatal mice

  2021cites this paper
• Characterization of atherosclerotic plaques in blood vessels with low oxygenated blood and blood pressure (Pulmonary trunk): role of growth differentiation factor-15 (GDF-15)

  2021cites this paper
• Cardio-renal safety of non-steroidal anti-inflammatory drugs.

  2019cites this paper
• Celecoxib aggravates atherogenesis and upregulates leukotrienes in ApoE-/- mice and lipopolysaccharide-stimulated RAW264.7 macrophages.

  2019cites this paper
• Regulatory T cells suppress the expression of COX-2 in vulnerable plaque

  2019cites this paper
• Microsomal Prostaglandin E Synthase-1–Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification

  2016cites this paper
• Celecoxib for the treatment of atherosclerosis

  2016cites this paper
• Could the thromboxane A2 pathway be a therapeutic target for the treatment of obstructive sleep apnea-induced atherosclerosis?

  2015cites this paper
• Prostaglandins and Other Lipid Mediators ould the thromboxane A 2 pathway be a therapeutic target for the reatment of OSA-induced atherosclerosis ?

  2015cites this paper
• Prostanoids, Their Receptors, and Atherogenesis

  2015cites this paper
• Metabolic disturbances and worsening of atherosclerotic lesions in ApoE-/- mice after cola beverages drinking

  2013cites this paper
• Mechanisms and Clinical Consequences of Vascular Calcification

  2012cites this paper
• Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis.

  2012cites this paper
• Eicosanoids in Atherosclerosis

  2012cites this paper
• Antagonism of the antithrombotic and anti‐atherosclerotic actions of aspirin by rofecoxib in the cholesterol‐fed rabbit

  2011cites this paper
• Arachidonic Acid Metabolites and the Kidney

  2011cites this paper
• Pathophysiology of Cyclooxygenases in Cardiovascular Homeostasis

  2010cites this paper
• Omega-3 fatty acids, inflammation and angiogenesis: basic mechanisms behind the cardioprotective effects of fish and fish oils.

  2010cites this paper
• Celecoxib combined with atorvastatin prevents progression of atherosclerosis.

  2010cites this paper
• Absence of Myeloid COX-2 Attenuates Acute Inflammation but Does Not Influence Development of Atherosclerosis in Apolipoprotein E Null Mice

  2010cites this paper
• Neither antioxidants nor genistein inhibit the progression of established atherosclerotic lesions in older apoE deficient mice.

  2009cites this paper
• Dietary Antioxidants and Genistein Do Not Inhibit the Progression of Established Atherosclerotic Lesions in Older Apo E Deficient Mice

  2009cites this paper
• The Journal of Toxicological Sciences

  2009cites this paper
• Vascular biology of eicosanoids and atherogenesis

  2009cites this paper
• Cyclooxygenase products and atherosclerosis.

  2008cites this paper
• Progression and disruption of advanced atherosclerotic plaques in murine models.

  2008cites this paper
• Serine palmitoyltransferase inhibitor myriocin induces the regression of atherosclerotic plaques in hyperlipidemic ApoE-deficient mice.

  2008cites this paper
• The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.

  2008cites this paper
• Prostanoid and isoprostanoid pathways in atherogenesis.

  2008cites this paper
• Untersuchungen an murinen Atherosklerose-Modellen zum Einfluss von Statinen und Cyclooxygenase-Hemmstoffen auf die vaskuläre Extrazellulärmatrix

  2008cites this paper
• Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice.

  2008cites this paper
• Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.

  2007cites this paper
• Chemokine Receptors in Atherosclerosis

  2007cites this paper
• Scientific Statement From the American Heart Association Use of Nonsteroidal Antiinflammatory Drugs : An Update for Clinicians: A

  2007cites this paper
• Assessment of Unstable Atherosclerosis in Mice

  2007cites this paper
• The role of phospholipases in lipid modification and atherosclerosis

  2007cites this paper
• Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.

  2007cites this paper
• Regulation of hyaluronan synthesis by vasodilatory prostaglandins

  2007cites this paper
• Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity?

  2007cites this paper
• COX-2 inhibitors and cardiovascular risk.

  2007cites this paper
• The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in ApoE−/− mice

  2007cites this paper
• Omega–3 Fatty Acids, Inflammation and Angiogenesis: Nutrigenomic Effects as an Explanation for Anti-Atherogenic and Anti-Inflammatory Effects of Fish and Fish Oils

  2007cites this paper
• Cyclooxygenase-2 Inhibition and Coagulation

  2006cites this paper
• Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships.

  2006cites this paper
• Update on cyclooxygenase-2 inhibitors.

  2006cites this paper
• Ruptures of delight? A new mouse model of plaque rupture.

  2006cites this paper
• Advisory From the American Heart Association The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science

  2006cites this paper
• Experimental Chlamydia pneumoniae infection model: Effects of repeated inoculations and treatment

  2006cites this paper
• Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis

  2006cites this paper
• Results TP Antagonism , but Not Combined Inhibition of COX-1 and COX-2 , Retards Atherogenesis in DKOs Fed a High-Fat Diet

  2005cites this paper
• CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin

  2005cites this paper
• Selective COX-2 Inhibitors and Risk of Myocardial Infarction

  2005cites this paper
• Omega-3 Fatty Acids and the Regulation of Expression of Endothelial Pro-Atherogenic and Pro-Inflammatory Genes

  2005cites this paper
• The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association.

  2005cites this paper
• Leukocyte Transglutaminase 2 Expression Limits Atherosclerotic Lesion Size

  2005cites this paper
• Review : Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs

  2005cites this paper
• Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice.

  2005cites this paper
• Chemistry and biology of vitamin E.

  2005cites this paper
• Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis.

  2005cites this paper
• Inhibition of cyclooxygenase with indomethacin phenethylamide reduces atherosclerosis in apoE-null mice.

  2005cites this paper
• mRNA expression of genes involved in lipid efflux and matrix degradation in occlusive and ectatic atherosclerotic disease

  2005cites this paper
• Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism

  2005cites this paper
• Cardiovascular complications of non-steroidal anti-inflammatory drugs.

  2005cites this paper
• Arsenic exposure exacerbates atherosclerotic plaque formation and increases nitrotyrosine and leukotriene biosynthesis.

  2004cites this paper
• Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress.

  2004cites this paper
• Lesion progression and plaque composition are not altered in older apoE-/- mice lacking tumor necrosis factor-alpha receptor p55.

  2004cites this paper
• Cyclooxygenase-2 and inflammation in atherosclerosis.

  2004cites this paper
• Atherosclerosis in the Apolipoprotein E – Deficient Mouse A Decade of Progress

  2004cites this paper
• Infection and inflammation in the cardiovascular system.

  2003cites this paper
• I nfection and inflammation in the cardiovascular system

  2003cites this paper
• Arteriosclerosis, Thrombosis

  year unknowncites this paper